Navigation Links
Amgen to Present at the Stifel Nicolaus Healthcare Conference
Date:9/2/2011

THOUSAND OAKS, Calif., Sept. 2, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the Stifel Nicolaus Healthcare Conference on Wednesday, Sept. 7, 2011 at the Four Seasons Hotel, Boston, Mass., beginning at 8:35 a.m. Eastern Time.  Arvind Sood, vice president of Investor Relations at Amgen, will present. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors.

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and vital medicines, visit www.amgen.com. Follow us on www.twitter.com/amgen.

CONTACT: Amgen, Thousand Oaks
Christine Regan, 805-447-5476 (media)
Arvind Sood, 805-447-1060 (investors)

(Logo: http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)


'/>"/>
SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
2. Medarex to Receive Milestone Payment from Amgen
3. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
4. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
5. CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
6. Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
7. Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
8. Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
9. Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP
10. Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
11. Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... CHAPEL HILL, N.C. , July 2, 2015 /PRNewswire/ ... industry. Because of its leading role in educating thought ... the functions that can heavily influence how well a ... to a new study from research and consulting leader ... Medical Affairs leaders need to focus on are early ...
(Date:7/2/2015)... Roche,s Bloodhound technology is on the ... hematology testing, according to Kalorama Information.  The healthcare ... its Bloodhound digital cell imaging technology –as newly ... hematology analyzer – is notable as a play ... leader CellaVision, but also compete more broadly in ...
(Date:7/2/2015)...   EVO Aesthetic Center and Wellness Spa ... aesthetics in Lakeway, Texas and ... Astanza Duality laser. The medical spa is focused on ... and laser procedures. Their addition of the Astanza Duality ... to their tattoo regret. "The large number ...
Breaking Medicine Technology:Medical Affairs Role in Thought Leader Education is Key Success Factor for New Product Launches in the Pharmaceutical Industry 2Kalorama: With Bloodhound, Roche Closes in on High-Growth Hematology Segment 2Kalorama: With Bloodhound, Roche Closes in on High-Growth Hematology Segment 3EVO Offers Advanced Laser Tattoo Removal With Astanza Duality In Lakeway, TX 2
... Progress in Advancing Second-Generation ... CCR9 Drug towards ... announced the completion of enrollment of 436 patients in the,company,s ... a Phase II/III clinical trial of Traficet-EN(TM),(CCX282-B) in patients with ...
... DIEGO, June 12 Vical Incorporated,(Nasdaq: VICL ... of cash payments,and equity investments from AnGes MG, ... funding of the company,s ongoing,Allovectin-7(R) Phase 3 metastatic ... equity investments, Vical has received $15.3 million to ...
Cached Medicine Technology:ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease 2ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease 3ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease 4ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease 5ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease 6Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial 2Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial 3Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial 4
(Date:7/3/2015)... ... 03, 2015 , ... Renowned rhinoplasty surgeon and Symposium Chairman, ... Rhinoplasty Symposium . To be held from March 4th - 6th, the 2016 (a ... Westin Galleria Dallas. , Designed to take participants from the basic training and fundamentals ...
(Date:7/3/2015)... ... 03, 2015 , ... Talcum powder attorneys representing clients in national lawsuits announce ... Lawsuit Center website. Just as the previous version did, the new website will serve ... updates and ovarian cancer warning information. The site is routinely updated with news articles ...
(Date:7/3/2015)... ... July 03, 2015 , ... Every year, One-to-1 Fitness ... where they provide members of the Red Deer community with free fitness training and ... fitness training, games, food, events and entertainment raised thousands of charity dollars and ended ...
(Date:7/2/2015)... ... July 02, 2015 , ... Following the recent report by JAMA Internal ... outnumber merely overweight Americans, Samir Becic emphatically declared a war on obesity in the ... now," Becic said. "We must understand the magnitude of this discovery. For that reason, ...
(Date:7/2/2015)... ... ... Achebe realized that the gift of poetry was fully in him, as beautiful phrases riddled ... three years later he was publishing an entire book of poetry. He knew there was ... always believed that the best way to lift yourself up, is in the effort of ...
Breaking Medicine News(10 mins):Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 2Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 3Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 2Health News:Talcum Powder Lawsuit News: Cancer Attorneys Launch Updated Mobile Site 3Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 2Health News:Red Deer Fitness Studio Raises $10,000 for Charity Organization with 24-Hour Train-a-Thon 3Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 2Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 3Health News:Samir Becic's Health Fitness Revolution Declares War Against Obesity in America 4Health News:Patrick Achebe Releases Debut Book, Whispering Waves: Poems for Everyday Grace 2
... Cancers and Colorectal Screening Among Key ProvisionsBETHESDA, Md., ... and its more than 10,000 physician members congratulate ... today for the introduction of "21st Century Cancer ... Treatment) Act" and their vow to renew the ...
... The ,Help is Here Express, bus tour will be ... 3 at various cities throughout the state in order ... programs that provide prescription medicines for free or nearly ... exceeding that of the nation (8.1 percent), the Partnership ...
... 26 BioMosaics Inc., a cancer biomarker ... antibody product (clone 1G12) for detection of ... as an immunohistochemical test for diagnosis of ... Laboratories is a state-of-the-art reference pathology laboratory ...
... average sodium intake far exceeds recommendations, raising health risks, ... American consumes far more salt each day than is ... from the U.S. Centers for Disease Control and Prevention ... high blood pressure, blacks, and middle-age and older adults ...
... new study by researchers at the University of British Columbia ... The study, published in the Journal of Public Health ... three times more likely than those who don,t to meet ... of physical activity. , Doctoral student Ugo Lachapelle and Assoc. ...
... Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY) and Genentech (NYSE: ... completed its acquisition of Genentech pursuant to a short-form ... the Roche Group. Roche had announced earlier in the ... expired on Wednesday, March 25. In connection with the ...
Cached Medicine News:Health News:Gastroenterologists Applaud Kennedy-Hutchinson Bill's Renewal of War on Cancer 2Health News:Gastroenterologists Applaud Kennedy-Hutchinson Bill's Renewal of War on Cancer 3Health News:Partnership for Prescription Assistance Prepared to Help Tennessee Workers Hurt by Recession 2Health News:Partnership for Prescription Assistance Prepared to Help Tennessee Workers Hurt by Recession 3Health News:BioMosaics' Glypican-3 Antibody (clone 1G12) Validated at PhenoPath Laboratories for Immunohistochemical Detection of Liver Cancer 2Health News:BioMosaics' Glypican-3 Antibody (clone 1G12) Validated at PhenoPath Laboratories for Immunohistochemical Detection of Liver Cancer 3Health News:Using Too Much Salt Is Common in U.S., CDC Says 2Health News:Public transit users 3 times more likely to meet fitness guidelines: UBC research 2Health News:Roche Completes Acquisition of Genentech 2
... Used for stone manipulation ... urinary tract. Enhanced wire ... dilation in the ureter. ... easy, ergonomic one-handed operation. ...
... Used for soft-tissue ... limited to paravaginal repairs, ... or rectocele. Surgisis® ES ... enhanced strength for intraoperative ...
... Used to provide drainage following open ... are employed to provide enhanced drainage ... provides maximum softness for enhanced patient ... to latex catheters. Supplied sterile in ...
... Reflotron Plus Chemistry Analyzer is an in ... determination of clinical chemistry parameters using Reflotron Test ... photometry and ensures rapid and reliable results while ... a clear LC display and the profile can ...
Medicine Products: